[144] Axon Enterprise, Inc. SEC Filing

Rhea-AI Filing Summary

In this Form 144 notice for Axon Enterprise, Inc., the filer reports an intended sale of 10,000 shares of common stock through UBS Financial Services on Nasdaq with an aggregate market value of $8,428,900 and an approximate sale date of 08/11/2025. The shares were acquired on 11/15/2021 via an option exercise and paid in cash. The filing lists 78,504,440 shares outstanding, so the proposed sale represents about 0.0127% of outstanding shares.

The form shows no securities sold by the filer in the past three months and includes the standard Rule 144 representation that the filer does not possess undisclosed material adverse information. A broker is named and the transaction mechanics (option exercise, cash payment) are disclosed.

Positive

• Regulatory compliance: Sale is filed under Rule 144 and identifies a broker (UBS), indicating formal disclosure and adherence to resale rules.
• Small relative size: 10,000 shares represent approximately 0.0127% of the 78,504,440 shares outstanding, limiting potential market impact.

Negative

• Insider sale disclosed: The filer is selling shares (aggregate value reported as $8,428,900); some investors may view insider sales negatively despite the small percentage of outstanding shares.

Insights

Financial Analyst

TL;DR Insider sale disclosed under Rule 144; the size is trivial relative to outstanding shares and unlikely to move the market.

The filer intends to sell 10,000 common shares valued at $8,428,900 via UBS with an approximate sale date of 08/11/2025. These shares were acquired by option exercise on 11/15/2021 and paid in cash, which clarifies consideration. Relative to 78,504,440 shares outstanding, the sale equals ~0.0127%, a negligible supply change. No sales were reported in the past three months, reducing evidence of sustained insider divestiture. Overall, informational and procedural clarity is present; impact on valuation or liquidity appears minimal.

Corporate Governance Expert

TL;DR The filing demonstrates compliance with Rule 144; disclosure is standard and does not show governance concerns from this notice alone.

The Form 144 names the broker (UBS Financial Services) and discloses acquisition via option exercise and cash payment, which are straightforward facts supporting transparency. The filer affirms no undisclosed material adverse information, and no reliance date for a 10b5-1 plan is provided on the form. From a governance perspective, the document is a routine insider liquidity disclosure and does not, by itself, indicate irregular insider activity or material corporate governance issues.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	10000	8428900.00	78504440	08/11/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/15/2021	Option Exercise	Issuer			10000	11/15/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Axon (AXON) disclose in this Form 144?

The filer disclosed intent to sell 10,000 common shares via UBS with an aggregate market value of $8,428,900 on or about 08/11/2025.

How were the securities being sold originally acquired?

The 10,000 shares were acquired on 11/15/2021 through an option exercise and payment was made in cash.

What proportion of Axon's outstanding shares does the sale represent?

The filing lists 78,504,440 shares outstanding; the proposed sale of 10,000 shares equals about 0.0127% of outstanding shares.

Were any other securities sold by the filer in the past three months?

The form reports Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The sale is to be executed through UBS Financial Services, Inc., Eleven Madison Avenue, New York, NY and the form indicates the securities exchange as Nasdaq.